News and Press Releases

Strengthening its Track Record of Successful Client Regulatory Approval Outcomes

SOUTHBOROUGH, MA – January 14, 2021 – Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)[i], and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe.

Leading the Organic and Acquisition Growth of Veristat Operations Throughout Europe

Delivering A Patient-Centric Approach to Recruitment and Retention for Clinical Trials

SOUTHBOROUGH, MA – December 7, 2020 –Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook.

Delivering on Customer Demand for Pharmacovigilance
from Clinical Trial Conduct to Post-Marketing Support

SOUTHBOROUGH, MA – October 22, 2020 – Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Veristat Enhances Patient-Centricity Offering by Delivering Clinical Trials
Directly to Patients

SOUTHBOROUGH, MA – September 30, 2020 – Veristat, a scientific-minded global clinical research organization (CRO), announced today the launch of a virtual clinical trial solution that is flexible and customizable so that patient interactions can be conducted at the clinical site, remotely at-home, or through a hybrid combination of both strategies.

In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. To date, this is one of the largest studies completed in Canada consisting of 360 patients with osteoarthritis (“OA”) of the knee, across 40 clinical sites.   

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle

Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors
 Along the Pathway to Market Approval

Veristat Expands Operations into Taiwan to Support Growing Client Demand for Clinical Trial, Biostatistics and Programming Excellence in the Region

Opens office in Taipei, Taiwan